Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 3, 2006, Pages 204-214

  Harkaway, R C ^a   Issa, M M ^b  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prostatic hyperplasia; Minimally invasive theraphy; Patient preference; Pharmacotheraphy

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ACUTE DISEASE; CATHETERIZATION; CHRONIC DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HEMATURIA; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; IMPOTENCE; INFORMED CONSENT; LIBIDO DISORDER; LOCAL ANESTHESIA; LONG TERM CARE; LOW LEVEL LASER THERAPY; MEDICAL DECISION MAKING; META ANALYSIS; MICROWAVE THERAPY; MINIMALLY INVASIVE SURGERY; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SYMPTOM; SYNCOPE; SYSTEMATIC REVIEW; TACHYPHYLAXIS; TRANSURETHRAL RESECTION; UNITED STATES; URETHRA DISEASE; URINARY TRACT INFECTION; URINE RETENTION; VAPORIZATION;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; MODELS, BIOLOGICAL; PRECANCEROUS CONDITIONS; PROSTATIC HYPERPLASIA; SURGICAL PROCEDURES, MINIMALLY INVASIVE; UNITED STATES;

EID: 33748253671     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500869     Document Type: Review

References (78)

1. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-547.
2. Gjertson CK, Walmsley K, Kaplan SA. Benign prostatic hyperplasia: Now we can begin to tailor treatment. Cleveland Clin J Med 2004; 71: 857, 860, 863-865.
3. Borth CS, Beiko DT, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: A decade of change. Urology 2001; 57: 1082-1085 (discussion 1085-1086).
4. Issa MM, Marshall FF. Contemporary Diagnosis and Management of Diseases of the Prostate, 3rd edn. Handbooks in Health Care Co.: Newtown, PA, 2005.
5. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-1261.
6. Speakman MJ. Initial choices and final outcomes in lower urinary tract symptoms. Eur Urol 2001; 40 (Suppl 4): 21-30.
7. National Institute of Diabetes and Digestive and Kidney Diseases. Kidney and Urologic Diseases Statistics for the United States. Available at http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/. (accessed July 21, 2005).
8. US Census Bureau. International Database, 2004.
9. Kirby RS, McConnell JD. Benign Prostatic Hyperplasia. Health Press: Oxford, 1995, pp 5-14.
10. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398.
11. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al., for the PLESS Study Group. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53: 473-480.
12. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
13. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA et al. Natural history of prostatism: Relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 1510-1515.
14. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999; 161: 1174-1179.
15. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600.
16. Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak, urinary flow rates in a community based cohort. J Urol 2000; 163: 107-113.
17. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk. Eur Urol 2001; 39: 390-399.
18. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997; 158: 481-487.
19. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA et al. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. J Urol 1999; 162: 1301-1306.
20. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991; 38 (Suppl): 4-8.
21. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A Department of Veterans Affairs co-operative study. J Urol 1998; 160: 12-16 (discussion 16-17).
22. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign Prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-563.
23. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, for the ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-495.
24. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE et al. Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825-831.
25. Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 2005; 95: 15-19.
26. Teillac P. Benign prostatic hyperplasia: Patients' perception of medical treatment and their expectations. Results of a French survey involving patients treated with finasteride [in French]. Therapie 2002; 57: 473-483.
27. Gee WF, Holtgrewe HL, Blute ML, Miles BJ, Naslund MJ, Nellans RE et al. 1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol 1998; 160: 1804-1807.
28. Wilson JR, Urwin GH, Stower MJ. The changing practice of transurethral prostatectomy: A comparison of cases performed in 1990 and 2000. Ann R Coll Surg Engl 2004; 86: 428-431.
29. Djavan B, Marberger M. Minimally invasive procedures as an alternative to medical management for lower urinary tract symptoms of benign prostatic hyperplasia. Curr Opin Urol 2001; 11: 1-7.
30. Djavan B, Seitz C, Marberger M. Heat versus drugs in the treatment of benign prostatic hyperplasia. BJU Int 2003; 91: 131-137.
31. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C et al. Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399-1403.
32. Carson III C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61: 2-7.
33. Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 1997; 10: 349-366.
34. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, for the ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-441.
35. Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology 2000; 56: 610-616.
36. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-2184.
37. Hagerty J, Ginsberg PC, Metro MJ, Harkaway RC. A prospective, comparative study of the onset of symptomatic benefit of dutasteride versus finasteride in men with benign prostatic hyperplasia in everyday clinical practice. Poster Presented at the Annual Meeting of the American Urological Association, May 8-13, 2004, San Francisco, CA.
38. Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol 2000; 38: 2-19.
39. de la Rosette JJ, Madersbacher S, Alivizatos G, Rioja Sanz C, Emberton M, Nordling J, for the European Association of Urology. Guidelines on benign prostatic hyperplasia. Available at http://www.uroweb.org/files/ uploaded_files/BPHDec2004-Webversion.pdf. (accessed on July 21, 2005).
40. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-466.
41. Bruskewitz R. Management of symptomatic BPH in the US: Who is treated and how? Eur Urol 1999; 36 (Suppl 3): 7-13.
42. 1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029-1035.
43. Chapple CR. A comparison of varying alpha-blockers and other pharmacotherapy options for lower urinary tract symptoms. Rev Urol 2005; 7 (Suppl 4): S22-S30.
44. Djavan B, Waldert M, Ghawidel C, Marberger M. Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 2004; 14: 45-50.
45. Hellstrom JG, Smith W, Sikka SC. Effects of alpha-blockers on ejaculatory function in normal subjects. J Urol 2005; 173: 237 (Abstract 874).
46. Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M. 5-Alpha-reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 2004; 45: 620-627.
47. Souverein PC, Erkens JA, de la Rosette JJ, Leufkens HG, Herings RM. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol 2003; 43: 528-534.
48. 1-blockers and watchful waiting. Urology 2005; 65: 300-305.
49. Larson TR. Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy. Urology 2002; 59 (Suppl 2A): 12-16.
50. de la Rosette JJ, Laguna MP, Gravas S, de Wildt MJ. Transurethral microwave thermotherapy: The gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia? J Endourol 2003; 17: 245-251.
51. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 2004; 172: 1404-1408.
52. Muschter R, Schorsch I, Danielli L, Russel C, Timoney A, Yachia D et al. Transurethral water-induced thermotherapy for the treatment of benign prostatic hyperplasia: A prospective multicenter clinical trial. J Urol 2000; 164: 1565-1569.
53. Trock BJ, Brotzman M, Utz WJ, Ugarte RR, Kaplan SA, Larson TR et al. Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia: Results at three months through four years. Urology 2004; 63: 716-721.
54. Zlotta AR, Djavan B. Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: Long-term data. Curr Opin Urol 2002; 12: 7-14.
55. Blute ML, Larsen T. Minimally invasive therapies for benign prostatic hyperplasia. Urology 2001; 58 (Suppl 6A): 33-41.
56. Vesely S, Knutson T, Dicuio M, Damber JE, Dahlstrand C. Transurethral microwave thermotherapy: Clinical results after 11 years of use. J Endourol 2005; 19: 730-733.
57. de la Rosette JJ, D'Ancona FC, Debruyne FM. Current status of thermotherapy of the prostate. J Urol 1997; 157: 430-438.
58. Walmsley K, Kaplan SA. Transurethral microwave thermotherapy for benign prostatic hyperplasia: Separating truth from marketing hype. J Urol 2004; 172: 1249-1255.
59. Buckingham CJ. Re: Transurethral microwave thermotherapy for benign prostatic hyperplasia: Separating truth from marketing hype. J Urol 2004; 172: 1249-1255.
60. Djavan B, Roehrborn CG, Shariat S, Ghawidel K, Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. J Urol 1999; 161: 139-143.
61. Djavan B, Shariat S, Fakhari M, Ghawidel K, Seitz C, Partin AW et al. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: A randomized, prospective clinical trial. Urology 1999; 53: 251-259.
62. Zlotta AR, Raviv G, Peny MO, Noel JC, Haot J, Schulman CC. Possible mechanism of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: A neurohistochemical study. J Urol 1997; 157: 894-899.
63. Braun M, Mathers M, Bondarenko B, Engelmann U. Treatment of benign prostatic hyperplasia through transurethral needle ablation (TUNA). Urol Int 2004; 72: 32-39.
64. Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171: 2336-2340.
65. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: Clinical outcome up to five years from three centers. Eur Urol 2003; 44: 89-93.
66. Boyle P, Robertson C, Vaughan ED, Fitzpatrick JM. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int 2004; 94: 83-88.
67. Naspro R, Salonia A, Colombo R, Cestari A, Guazzoni G, Rigatti P et al. Update of the minimally invasive therapies for benign prostatic hyperplasia. Curr Opin Urol 2005; 15: 49-53.
68. Issa MM, Townsend M, Jiminez VK, Miller LE, Anastasia K. A new technique of intraprostatic fiber placement to minimize thermal injury to prostatic urothelium during indigo interstitial thermal therapy. Urology 1998; 51: 105-110.
69. Kursch ED, Concepcion R, Chan S, Hudson P, Ratner M, Eyre R. Interstitial laser coagulation versus transurethral prostate resection for treating benign prostatic obstruction: A randomized trial with 2-year follow-up. Urology 2003; 61: 573-578.
70. Djavan B, Marberger M. Minimally invasive procedures and medical management - their relative merits in treating lower urinary tract symptoms of benign prostatic hyperplasia. Rev Urol 2000; 2: 105-114.
71. Naslund MJ, Carlson AM, Williams MJ. A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period. J Urol 2005; 173: 2090-2093.
72. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004; 5: 251-257.
73. Carbone Jr DJ, Hodges S. Medical therapy for benign prostatic hyperplasia: Sexual dysfunction and impact on quality of life. Int J Impot Res 2003; 15: 299-306.
74. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-649.
75. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical 'aging male' symptoms? Results of the Cologne Male Survey. Eur Urol 2003; 44: 588-594.
76. Hoesl CE, Woll EM, Burkart M, Altwein JE. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005; 47: 511-517.
77. National Institute of Diabetes and Digestive and Kidney Diseases. Minimally invasive surgical therapies (MIST) treatment consortium for benign prostatic hyperplasia (BPH). Available at http://www.niddk.nih.gov/patient/mist/mist.htm. (accessed July 21, 2005).
78. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000; 37: 367-380.